Thoracic Endograft Trial Non-Randomization Provokes FDA Panel Criticism

Lack of randomization in studies assessing Gore's TAG thoracic endograft emerged as a problem area during the FDA Circulatory System Devices Panel's review of the device Jan. 13

More from Archive

More from Medtech Insight